Skip to content

Study · Measured the body's own peptide · 2026

1 result

Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application.

Jin M, Xu F, Liu Y, Jiang Z

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association6 Feb 2026Cited by 1 (Europe PMC)

PMID41655688 (opens in a new tab)DOI10.1016/j.fct.2026.116002 (opens in a new tab)PepBankPUB-41655688
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In a randomized trial, daily intake of Limosilactobacillus fermentum LF61 for 8 weeks increased serum levels of the body's own LL‑37.

    In plain wordsIn a randomized trial, a probiotic taken daily for 8 weeks raised the body's own LL‑37 level in blood.

    Peptide
    LL-37
    Outcome
    IncreaseSerum LL-37 level
    Study

    n = 49

    Outcome group
    Immune response · Immune and inflammation

    Measurements

    Serum LL-37 increase
    12.3%
    LF61 group

    Source sentences

    Summary
    In a randomized, double-blind clinical trial (n = 49), daily intake of 3 × 1010 CFU of LF61 for 8 weeks increased serum levels of the antimicrobial peptide LL-37 by 12.3% (p < 0.05), and IgA, IgG, and IgM by 18.7%, 15.2%, and 9.8%, respectively (p < 0.05).

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.